ABVC BioPharma, Inc. (NASDAQ: ABVC) announced the planned spin-off of its wholly owned subsidiary BioKey (Cayman), Inc. through a pro rata dividend distribution of BioKey ordinary shares to ABVC shareholders. The distribution, subject to regulatory steps including the effectiveness of a Form 10 registration statement by June 25, 2026, will grant eligible shareholders approximately 4,500,000 ordinary shares, representing about 15% of BioKey's outstanding shares. The record date is set for July 24, 2026, with the distribution effective as of August 3, 2026.
BioKey operates as a nutraceutical and functional-supplement research, development, and manufacturing company through its California subsidiary, BioKey, Inc. It functions as a fully integrated Contract Research and Development and Manufacturing Organization (CRDMO), offering services including preclinical and clinical trial contract research, active pharmaceutical ingredient analysis, drug formulation and analytical method development, clinical trial material production under cGMP conditions, and FDA-compliant regulatory filing support. BioKey holds four FDA-approved Abbreviated New Drug Applications (ANDAs) and operates a cGMP-certified facility in Fremont, California. The company also plans to integrate artificial intelligence technology into its services in the future.
ABVC shareholders are not required to take any action to receive the dividend, and no consideration is required. The distribution will be handled in book-entry form by VStock Transfer, LLC, acting as distribution agent. Following the spin-off, BioKey intends to apply for its ordinary shares to be quoted on the OTC Markets, though there is no guarantee that a trading market will develop. Until such quotation, shareholders will be unable to sell or transfer their BioKey shares in the public market. ABVC common stock will continue trading on Nasdaq under the symbol "ABVC."
Dr. Uttam Patil, ABVC's CEO, stated, "We believe the BioKey transaction provides an opportunity to highlight the underlying value of our businesses while maintaining our commitment to long-term shareholder value creation." The spin-off is part of ABVC's strategy to unlock value from its subsidiaries and technology platforms, providing shareholders with direct participation in BioKey's future growth. ABVC continues to evaluate opportunities across its biotechnology, artificial intelligence, healthcare, and commercial services portfolio for additional value-enhancing transactions.
ABVC BioPharma is a clinical-stage biopharmaceutical company with a pipeline of six drugs and one medical device (ABV-1701/Vitargus®) under development. It utilizes in-licensed technology from research institutions including Stanford University, University of California at San Francisco, and Cedars-Sinai Medical Center. For more details on the spin-off, the company has filed a Registration Statement on Form 10 with the SEC, which includes an Information Statement. Investors can access these documents free of charge on the SEC's website at http://www.sec.gov.
This announcement is significant for ABVC shareholders as it provides a direct stake in a separate entity focused on the growing nutraceutical and CDMO markets, potentially enhancing overall shareholder value. For the industry, the spin-off highlights a trend of biopharma companies separating subsidiary businesses to unlock valuation and strategic flexibility. The integration of AI into BioKey's services could also signal advancements in contract research and manufacturing efficiency.
